Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984376 | 1.00 | EPHX1 (0.48) | EPHX1SIGMAR1PAOXKDM4AKDM4C | |
| SCHEMBL2387428 | 0.92 | — | — | |
| SCHEMBL3425766 | 0.86 | KDM4E (0.30) | — | |
| SCHEMBL3583741 | 0.83 | — | — | |
| SCHEMBL2386124 | 0.80 | — | — | |
| SCHEMBL10873634 | 0.79 | EPHX1 (0.48) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL9661841 | 0.79 | EPHX1 (0.48) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL76962 | 0.79 | EPHX1 (0.48) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL148471 | 0.79 | EPHX1 (0.48) | EPHX1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL149027 | 0.79 | EPHX1 (0.48) | EPHX1S1PR2S1PR4S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | EPHX1 3034/4885SIGMAR1 505/4885PAOX 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.